Telitacicept as a novel treatment for refractory lupus nephritis complicated by podocytic infolding glomerulopathy  

作　　者：Lu Zhou Haoguang Li Rongwei Zhang Qifeng Jiang Xinwang Duan 

机构地区：[1]Department of Rheumatology and Immunology,The Second Affiliated Hospital,Jiangxi Medical College,Nanchang University,Nanchang,China [2]Department of Pathology,Guangzhou Huayin Medical Laboratory Center,Guangzhou,China

出　　处：《Rheumatology & Autoimmunity》2024年第3期186-188,共3页风湿病与自身免疫（英文）

基　　金：National Key Research and Development Program of China(2021YFC2501304);Science and Technology Program of Department of Health of Jiangxi Province(20204254);Key Research and Development Program of Jiangxi Municipal Science and Technology Department(20192BBGL70024).

摘　　要：To the Editor,Lupus nephritis(LN),a renal symptom of systemic lupus erythematosus(SLE),frequently causes severe organ damage in SLE patients.1 There is no consensus on the definition of refractory LN,which has been suggested to occur when remission is not achieved after 3–12 months of combined glucocorticoids and immunosuppressive therapy.2 Podocytic infolding glomerulopathy(PIG),a rare type of glomerular morphological alteration,is primarily characterized by the presence of microspheres,microtubular structures,or a combination of the two,which are associated with podocyte infolding into the glomerular basement membrane(GBM).3,4 The exact pathogenesis of PIG remains unclear,but it may be associated with autoimmune diseases like SLE and Sjögren's syndrome.The occurrence of refractory LN complicated by PIG is rare and poses significant challenges in management.Here,we endeavor to provide the patient with benefits by employing a novel treatment,Telitacicept,which has demonstrated the potential to achieve complete renal remission in such cases.

关 键 词：NEPHRITIS LUPUS LUPUS 

分 类 号：R692[医药卫生—泌尿科学]